Risk-Based Management Guidelines for Abnormal Cervical Cancer Screening Tests and Pre-Cervical Cancer Stage
Risk-Based Management Guidelines for Cervical Cancer Screening
Keywords:
cervical cytology, pre-cancerous stages, management of abnormal cervical screening tests, guidelines, cervical intraepithelial neoplasia (CIN)Abstract
Pre-cancerous screening for cervical cancer can significantly reduce the incidence and mortality of cervical cancer. Its success depends on the screening system. Over the years, clinical practice guidelines have been established in the care of women with abnormal cervical screening results and pre-cancerous cervical screenings to improve service quality. While knowledge and technology have increased and developed rapidly. It is important to continuously update clinical practice guidelines. The American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines for the care of abnormal cervical screening results and pre-cancerous stages have been revised in 2019 based on the original concept of the previous year. It is based on the original concept of the 2012 guidelines, which is risk-based, but has been applied more broadly and comprehensively. The new guideline focuses on comprehensive, risk-based care for each patient, using current results combined with a history of past results to calculate a patient's current and future risk of cervical intraepithelial neoplasia grade 3 or more severe (CIN 3+). This paper presents a review of the guidelines and relevant empirical evidence aiming to spread awareness about new guidelines for the care of abnormal cervical screening outcomes and pre-cancerous stages
References
1. Insamran W, Sangrajrang S. National Cancer Control Program of Thailand. Asian Pac J Cancer Prev 2020;21(3):577-82.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209-49.
3. Thanapprapasr D, Deesamer S, Sujintawong S, Udomsubpayakul U, Wilailak S. Cervical cancer screening behaviours among Thai women: results from a cross-sectional survey of 2112 healthcare providers at Ramathibodi Hospital, Thailand. Eur J Cancer Care (Engl) 2012;21(4):542-7.
4. Niu L, Virani S, Bilheem S, Sriplung H. The effect of Pap smear screening on cervical cancer stage among southern Thai women. Sci Rep 2019;9(1):16921. doi: 10.1038/s41598-019-52607-6
5. Mukem S, Meng Q, Sriplung H, Tangcharoensathien V. Low coverage and disparities of breast and cervical cancer screening in Thai women: analysis of National Representative Household Surveys. Asian Pac J Cancer Prev 2015;16(18):8541-51.
6. Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2020;24(2):102-31.
7. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 Updated Consensus Guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 2013;121(4):829-46.
8. Egemen D, Cheung LC, Chen X, Demarco M, Perkins RB, Kinney W, et al. Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. J Low Genit Tract Dis 2020;24(2):132-43.
9. Fontham ETH, Wolf AMD, Church TR, Etzioni R, Flowers CR, Herzig A, et al. Cervical cancer screening for individuals at average risk: 2020 Guideline Update from the American Cancer Society. CA Cancer J Clin 2020;70(5):321-46.
10. Schiffman M, Wentzensen N, Perkins RB, Guido RS. An introduction to the 2019 ASCCP Risk-Based Management Consensus Guidelines. J Low Genit Tract Dis 2020; 24(2):87-9.
11. Cheung LC, Egemen D, Chen X, Katki HA, Demarco M, Wiser AL, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines: methods for risk estimation, recommended management, and validation. J Low Genit Tract Dis 2020;24(2):90-101.
12. Castle PE, Xie X, Xue X, Poitras NE, Lorey TS, Kinney WK, et al. Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results. Prev Med 2019;118:44-50.
13. Demarco M, Egemen D, Raine-Bennett TR, Cheung LC, Befano B, Poitras NE, et al. A Study of Partial Human Papillomavirus Genotyping in Support of the 2019 ASCCP Risk-Based Management Consensus Guidelines. J Low Genit Tract Dis 2020;24(2):144-7.
14. Teoh D, Musa F, Salani R, Huh W, Jimenez E. Diagnosis and management of adenocarcinoma in situ: A Society of Gynecologic Oncology Evidence-Based Review and Recommendations. Obstet Gynecol 2020;135(4):869-78.
15. Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis 2012;16(3):205-42.
16. Darragh TM, Colgan TJ, Thomas Cox J, Heller DS, Henry MR, Luff RD, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol 2013;32(1):76-115.
17. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in Clinical practice. J Natl Cancer Inst 2005;97(14):1072-9.
18. Strander B, Andersson-Ellstrom A, Milsom I, Sparen P. Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. BMJ 2007;335(7629):1077.
19. Marcus JZ, Cason P, Downs LS Jr, Einstein MH, Flowers L. The ASCCP cervical cancer screening task force endorsement and opinion on the American Cancer Society Updated Cervical Cancer Screening Guidelines. J Low Genit Tract Dis 2021;25(3):187-91.
20. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;357(16):1579-88.
21. Castle PE, Kinney WK, Xue X, Cheung LC, Gage JC, Zhao FH, et al. Effect of several negative rounds of human papillomavirus and cytology co-testing on safety against cervical cancer: An Observational Cohort Study. Ann Intern Med 2018;168(1):20-9.
22. Schiffman M, Kinney WK, Cheung LC, Gage JC, Fetterman B, Poitras NE, et al. Relative performance of HPV and cytology components of cotesting in cervical screening. J Natl Cancer Inst 2018;110 (5):501-8.
23. Demarco M, Cheung LC, Kinney WK, Wentzensen N, Lorey TS, Fetterman B, et al. Low risk of cervical cancer/precancer among most women under surveillance postcolposcopy. J Low Genit Tract Dis 2018;22(2):97-103.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209-49.
3. Thanapprapasr D, Deesamer S, Sujintawong S, Udomsubpayakul U, Wilailak S. Cervical cancer screening behaviours among Thai women: results from a cross-sectional survey of 2112 healthcare providers at Ramathibodi Hospital, Thailand. Eur J Cancer Care (Engl) 2012;21(4):542-7.
4. Niu L, Virani S, Bilheem S, Sriplung H. The effect of Pap smear screening on cervical cancer stage among southern Thai women. Sci Rep 2019;9(1):16921. doi: 10.1038/s41598-019-52607-6
5. Mukem S, Meng Q, Sriplung H, Tangcharoensathien V. Low coverage and disparities of breast and cervical cancer screening in Thai women: analysis of National Representative Household Surveys. Asian Pac J Cancer Prev 2015;16(18):8541-51.
6. Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2020;24(2):102-31.
7. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 Updated Consensus Guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 2013;121(4):829-46.
8. Egemen D, Cheung LC, Chen X, Demarco M, Perkins RB, Kinney W, et al. Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. J Low Genit Tract Dis 2020;24(2):132-43.
9. Fontham ETH, Wolf AMD, Church TR, Etzioni R, Flowers CR, Herzig A, et al. Cervical cancer screening for individuals at average risk: 2020 Guideline Update from the American Cancer Society. CA Cancer J Clin 2020;70(5):321-46.
10. Schiffman M, Wentzensen N, Perkins RB, Guido RS. An introduction to the 2019 ASCCP Risk-Based Management Consensus Guidelines. J Low Genit Tract Dis 2020; 24(2):87-9.
11. Cheung LC, Egemen D, Chen X, Katki HA, Demarco M, Wiser AL, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines: methods for risk estimation, recommended management, and validation. J Low Genit Tract Dis 2020;24(2):90-101.
12. Castle PE, Xie X, Xue X, Poitras NE, Lorey TS, Kinney WK, et al. Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results. Prev Med 2019;118:44-50.
13. Demarco M, Egemen D, Raine-Bennett TR, Cheung LC, Befano B, Poitras NE, et al. A Study of Partial Human Papillomavirus Genotyping in Support of the 2019 ASCCP Risk-Based Management Consensus Guidelines. J Low Genit Tract Dis 2020;24(2):144-7.
14. Teoh D, Musa F, Salani R, Huh W, Jimenez E. Diagnosis and management of adenocarcinoma in situ: A Society of Gynecologic Oncology Evidence-Based Review and Recommendations. Obstet Gynecol 2020;135(4):869-78.
15. Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis 2012;16(3):205-42.
16. Darragh TM, Colgan TJ, Thomas Cox J, Heller DS, Henry MR, Luff RD, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol 2013;32(1):76-115.
17. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in Clinical practice. J Natl Cancer Inst 2005;97(14):1072-9.
18. Strander B, Andersson-Ellstrom A, Milsom I, Sparen P. Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. BMJ 2007;335(7629):1077.
19. Marcus JZ, Cason P, Downs LS Jr, Einstein MH, Flowers L. The ASCCP cervical cancer screening task force endorsement and opinion on the American Cancer Society Updated Cervical Cancer Screening Guidelines. J Low Genit Tract Dis 2021;25(3):187-91.
20. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;357(16):1579-88.
21. Castle PE, Kinney WK, Xue X, Cheung LC, Gage JC, Zhao FH, et al. Effect of several negative rounds of human papillomavirus and cytology co-testing on safety against cervical cancer: An Observational Cohort Study. Ann Intern Med 2018;168(1):20-9.
22. Schiffman M, Kinney WK, Cheung LC, Gage JC, Fetterman B, Poitras NE, et al. Relative performance of HPV and cytology components of cotesting in cervical screening. J Natl Cancer Inst 2018;110 (5):501-8.
23. Demarco M, Cheung LC, Kinney WK, Wentzensen N, Lorey TS, Fetterman B, et al. Low risk of cervical cancer/precancer among most women under surveillance postcolposcopy. J Low Genit Tract Dis 2018;22(2):97-103.
Downloads
Published
2021-08-30
Issue
Section
Review Article
